Systemic and Ocular Safety of Ciprofloxacin Ophthalmic Solution (Ciloxan) in Immature Animals

  title={Systemic and Ocular Safety of Ciprofloxacin Ophthalmic Solution (Ciloxan) in Immature Animals},
  author={J. Heaton and Robert B. Hackett},
  journal={Journal of Toxicology-cutaneous and Ocular Toxicology},
  • J. Heaton, R. Hackett
  • Published 1993
  • Medicine, Biology
  • Journal of Toxicology-cutaneous and Ocular Toxicology
AbstractQuinolone antimicrobials have been associated with arthropathy following oral administration for 7 days to immature animals. Therefore, the oral dosage form contains label restrictions for use in children. This study was designed to evaluate the toxicity potential of ciprofloxacin ophthalmic solution (Ciloxan) on the developing bones and joints of immature dogs. Three groups of four dogs, two/sex/group, 8 weeks old, were treated with 0.3% or 0.75% ciprofloxacin ophthalmic solution four… 


Toxicological studies on pipemidic acid. V. Effect on diarthrodial joints of experimental animals.
Pipemidic acid (PPA) orally given in a dose of 100 mg/kg/day or more was found to cause lame gait in immature beagle dogs of about 3 months old and the gait abnormality was almost disappeared spontaneously even if medication was continued.
Ciprofloxacin: an overview of adverse experiences.
  • P. Ball
  • Medicine
    The Journal of antimicrobial chemotherapy
  • 1986
Ciprofloxacin appears to have an excellent safety profile and little evidence of significant haematological or biochemical toxicity, other than a few reports of transient neutropenia and the finding of equally transient, usually trivial and invariably reversible elevations of serum aminotransferases.
Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin.
The results together with the published data on quinolone use in pediatrics suggest that ciprofloxacin does not cause arthropathy in humans.
Ciprofloxacin in acute exacerbations of chronic bronchitis.
Thirty four patients with acute purulent exacerbations of chronic bronchitis were treated with 500 mg ciprofloxacin twice daily, orally, for ten days with no significant differences in responses between pneumococcal and Haemophilus infections during and after therapy.
Role of the new quinolones in pediatric practice.
  • U. Schaad
  • Medicine
    The Pediatric infectious disease journal
  • 1992